Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

576
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
576
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

969
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
969
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.1K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

391
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
391
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

332
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
332
Depression: Overview01:18

Depression: Overview

556
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
556

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relationship between maternal experiences of abuse and maternal sensitivity in early mother-infant interactions.

Journal of reproductive and infant psychology·2026
Same author

A qualitative investigation of young people's experiences and views of Early Support Hubs across England.

PloS one·2026
Same author

Can whole-family interventions target violence and parenting in families experiencing domestic violence and abuse? A longitudinal study of the For Baby's Sake programme.

BMC psychology·2026
Same author

The association between adverse childhood experiences (ACEs) and gestational diabetes mellitus (GDM): A systematic review and meta-analysis.

Diabetes research and clinical practice·2026
Same author

Maternal glycaemia and child educational attainment at age 5 in the Born in Bradford cohort.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative.

Pediatric blood & cancer·2026

Related Experiment Video

Updated: Nov 17, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.1K

Antidepressant treatment for postnatal depression.

Jennifer Valeska Elli Brown1,2, Claire A Wilson3, Karyn Ayre3

  • 1Mental Health and Addiction Research Group, Department of Health Sciences, University of York, York, UK.

The Cochrane Database of Systematic Reviews
|February 13, 2021
PubMed
Summary

Selective serotonin reuptake inhibitors (SSRIs) may offer benefits for postnatal depression response and remission compared to placebo. However, evidence quality is low, necessitating further research on antidepressant effectiveness and safety for mothers and infants.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

359
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.9K

Related Experiment Videos

Last Updated: Nov 17, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.1K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

359
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.9K

Area of Science:

  • Perinatal mental health
  • Pharmacological interventions
  • Evidence-based medicine

Background:

  • Postnatal depression is a common complication affecting mothers, infants, and families.
  • Treatment options include psychosocial interventions and antidepressant medications.
  • This review updates previous analyses on antidepressant effectiveness for postnatal depression.

Purpose of the Study:

  • To evaluate the effectiveness and safety of antidepressant drugs for postnatal depression.
  • To compare antidepressants against placebo, treatment as usual, or other interventions.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searched major databases (Cochrane, MEDLINE, Embase, PsycINFO) and trial registries.
  • Included 11 RCTs involving 1016 women with depression within 12 months postpartum.

Main Results:

  • Selective serotonin reuptake inhibitors (SSRIs) showed potential benefits over placebo for response (55% vs. 43%) and remission (42% vs. 27%).
  • Reduced depressive symptoms observed with SSRIs (SMD -0.30), but evidence quality was low to very low.
  • No significant differences in acceptability or adverse events between SSRIs and placebo; limited data on infant outcomes.

Conclusions:

  • Limited evidence exists for antidepressant effectiveness and safety in postnatal depression, especially for severe cases.
  • Low-certainty evidence suggests SSRIs may improve response and remission rates compared to placebo.
  • Further research with larger samples and longer follow-up is crucial to inform clinical decisions and individualized risk-benefit assessments.